Longeveron (LGVN) Operating Income (2020 - 2026)
Longeveron's (LGVN) quarterly Operating Income came in at -$4.8 million in Q1 2026, up 7.84% year-on-year from -$4.4 million in Q1 2025, and up 11.56% quarter-over-quarter from -$5.4 million in Q4 2025.
Longeveron (LGVN) Operating Income (2020 - 2026) Analysis & Trends
Longeveron's Operating Income history runs 7 years deep, the most recent figure standing at -$4.8 million for Q1 2026.
- On a quarterly basis, Operating Income rose 7.84% year-over-year to -$4.8 million in Q1 2026; TTM through Mar 2026 was -$22.9 million, a 29.92% decrease from a year earlier, with the FY2025 full-year figure at -$23.3 million, down 40.95% from the prior year.
- Operating Income advanced to -$4.8 million in Q1 2026 per LGVN's latest filing, from -$5.4 million in the prior quarter.
- Across five years, Operating Income topped out at -$3.4 million in Q1 2022 and bottomed at -$7.3 million in Q3 2025.
- The 5-year median for Operating Income is -$5.2 million (2023), against an average of -$4.9 million.
- Across the five-year window, Operating Income soared 38.73% in 2024 and slumped 57.24% in 2025, its largest moves.
- Year by year, Operating Income stood at -$5.2 million in 2022, then slipped by 3.8% to -$5.4 million in 2023, then advanced by 21.31% to -$4.3 million in 2024, then slipped by 26.12% to -$5.4 million in 2025, then grew by 11.56% to -$4.8 million in 2026.
- Per Business Quant, the three latest LGVN Operating Income figures stand at -$4.8 million (Q1 2026), -$5.4 million (Q4 2025), and -$7.3 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 249.90 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.72 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 493.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -445.22 Mn |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | -4.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.78 Mn |
| Dec 31, 2025 | -5.40 Mn |
| Sep 30, 2025 | -7.31 Mn |
| Jun 30, 2025 | -5.40 Mn |
| Mar 31, 2025 | -5.18 Mn |
| Dec 31, 2024 | -4.28 Mn |
| Sep 30, 2024 | -4.65 Mn |
| Jun 30, 2024 | -3.50 Mn |
| Mar 31, 2024 | -4.09 Mn |
| Dec 31, 2023 | -5.44 Mn |
| Sep 30, 2023 | -5.16 Mn |
| Jun 30, 2023 | -5.71 Mn |
| Mar 31, 2023 | -4.72 Mn |
| Dec 31, 2022 | -5.24 Mn |
| Sep 30, 2022 | -5.19 Mn |
| Jun 30, 2022 | -4.22 Mn |
| Mar 31, 2022 | -3.39 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | -4.91 Mn |
| Jun 30, 2021 | -5.06 Mn |